Related Experiment Video
Updated: Jun 17, 2026
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Surgical resection of vulva lymphoedema circumscriptum
Stéphane Vignes1, Maria Arrault, Patrick Trévidic
1Department of Lymphology, Hôpital Cognacq-Jay, 15, rue Eugène Millon, 75015 Paris, France. stephane.vignes@hopital-cognacq-jay.fr
Insights
Surgical resection effectively treats vulva lymphangioma circumscriptum (VLC), a rare lymphatic malformation. While recurrence is common, repeat surgeries offer a well-tolerated solution for symptom relief.
Area of Science:
- Dermatology
- Plastic Surgery
- Gynecology
Background:
- Lymphangioma circumscriptum (LC) is a rare benign condition affecting dermal and subcutaneous lymphatics.
- It can be congenital or acquired, presenting challenges in management.
Purpose of the Study:
- To evaluate the efficacy of surgical resection for vulva lymphangioma circumscriptum (VLC).
Main Methods:
- A retrospective analysis of eight women treated surgically for VLC between 2000 and 2008.
- All patients underwent surgery by a specialist in lymphatic diseases.
Main Results:
- Seven out of eight women achieved symptom resolution after a median follow-up of 53 months post-last surgery.
- Recurrence occurred in five women, necessitating repeat resections (one or two additional surgeries).
- Post-surgical lymph oozing was moderate and transient in five patients.
Conclusions:
- Surgical resection is a safe and effective treatment for VLC in most cases.
- Despite frequent recurrence, repeated surgical interventions are well-tolerated and lead to symptom-free outcomes.
Background:
Lymphangioma circumscriptum, a rare, benign disease that can be either congenital or acquired, involves the deep dermis and subcutaneous lymphatics.
Objective:
This study aims to analyse the efficacy of surgical resection of vulva lymphangioma circumscriptum (VLC).
Materials And Methods:
Between January 2000 and December 2008, eight consecutive women referred to our centre and treated surgically for VLC were included in the study. VLC was responsible for recurrent lymph oozing in seven cases. All women were treated by the same plastic surgeon specialising in lymphatic diseases.
Results:
The first surgery was performed after a median interval of 5.4 years since VLC onset. The first cutaneous resection included the labia majora of all women and labia minora of five and clitoral hood of four. Five women experienced rapidly recurrent vesicles associated with lymph oozing and underwent resection again (once: two women, twice: three women). The second resection was performed 4-6 months after the first, whereas the third took place 1-6 years after the second. Five women had moderate and transitory post-surgical lymph oozing. After a median follow-up of 53 months after the last surgery, seven of the eight women were free from symptom.
Conclusion:
Surgical resection is an effective and well-tolerated therapy for VLC in most women. Lesion recurrence is frequent but resection can be repeated several times with no adverse effects.
